CN1681557A - 治疗碳酸酐酶介导的疾病的方法 - Google Patents
治疗碳酸酐酶介导的疾病的方法 Download PDFInfo
- Publication number
- CN1681557A CN1681557A CNA038218801A CN03821880A CN1681557A CN 1681557 A CN1681557 A CN 1681557A CN A038218801 A CNA038218801 A CN A038218801A CN 03821880 A CN03821880 A CN 03821880A CN 1681557 A CN1681557 A CN 1681557A
- Authority
- CN
- China
- Prior art keywords
- group
- hydrocarbyl
- alkyl
- halo
- carbonic anhydrase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/213,793 US20030100594A1 (en) | 2001-08-10 | 2002-08-07 | Carbonic anhydrase inhibitor |
| US10/213,793 | 2002-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1681557A true CN1681557A (zh) | 2005-10-12 |
Family
ID=31714232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA038218801A Pending CN1681557A (zh) | 2002-08-07 | 2003-02-14 | 治疗碳酸酐酶介导的疾病的方法 |
Country Status (12)
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102351793A (zh) * | 2011-08-30 | 2012-02-15 | 江苏正大清江制药有限公司 | 4-[3-(4-甲基苯基)-5-(三氟甲基)-1-氢-吡唑-1-基]苯磺酰胺的直接合成方法 |
| CN102574782A (zh) * | 2009-10-21 | 2012-07-11 | 拜耳医药股份有限公司 | 取代的卤代苯氧基苯甲酰胺衍生物 |
| CN109557309A (zh) * | 2018-12-04 | 2019-04-02 | 九江学院附属医院 | 碳酸酐酶-2作为检测标记物在肾结石诊断方面的应用 |
| CN111233786A (zh) * | 2020-02-04 | 2020-06-05 | 中国人民解放军军事科学院军事医学研究院 | 含五元杂环的苯磺酰胺类化合物及其制备方法和用途 |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6946243B2 (en) * | 2000-07-20 | 2005-09-20 | Solvay Pharmaceuticals Gmbh | Method of identifying compounds suitable for treatment and/or prophylaxis of obesity |
| DE10035227A1 (de) * | 2000-07-20 | 2002-01-31 | Solvay Pharm Gmbh | Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind |
| US20100135980A1 (en) * | 2000-10-16 | 2010-06-03 | Rodriguez Victorio C | Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging, disorders of aging, cancer, as growth factors, and as an alternative to stem cell therapy |
| US20030220376A1 (en) * | 2001-08-10 | 2003-11-27 | Pharmacia Corporation | Methods for treating carbonic anhydrase mediated disorders |
| ES2436524T3 (es) | 2003-05-22 | 2014-01-02 | Nerviano Medical Sciences S.R.L. | Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas |
| WO2005079781A1 (en) * | 2004-02-25 | 2005-09-01 | La Trobe University | Therapeutic and/or prophylactic method |
| WO2005094815A1 (en) * | 2004-03-30 | 2005-10-13 | Amorepacific Corporation | Dual inhibition of cyclooxygenase-2 and carbonic anhydrase |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| CA2609185A1 (en) | 2005-05-20 | 2006-11-30 | Ahmed F. Abdel-Magid | Process for preparation of sulfamide derivatives |
| JP4872076B2 (ja) * | 2005-09-15 | 2012-02-08 | 国立大学法人 長崎大学 | 硝子体可視化剤 |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US20070155823A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| AU2007253814A1 (en) | 2006-05-19 | 2007-11-29 | Janssen Pharmaceutica N.V. | Co-therapy for the treatment of epilepsy |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| WO2008075148A2 (en) * | 2006-12-15 | 2008-06-26 | Pfizer Products Inc. | Tricyclic inhibitors of carbonic anhydrase |
| CA2711678A1 (en) * | 2008-01-09 | 2009-07-16 | Molecular Insight Pharmaceuticals, Inc. | Inhibitors of carbonic anhydrase ix |
| WO2010008776A2 (en) | 2008-06-23 | 2010-01-21 | Janssen Pharmaceutica Nv | Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems |
| US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| AU2009322167B2 (en) | 2008-12-05 | 2014-11-20 | Molecular Insight Pharmaceuticals, Inc. | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA |
| WO2010065899A2 (en) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof |
| US8211402B2 (en) | 2008-12-05 | 2012-07-03 | Molecular Insight Pharmaceuticals, Inc. | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer |
| WO2010125004A1 (en) * | 2009-04-29 | 2010-11-04 | Nerviano Medical Sciences S.R.L. | Cdk inhibitor salts |
| BR112012000209B8 (pt) | 2009-06-15 | 2021-07-27 | Molecular Insight Pharm Inc | heterodímeros de ácido glutâmico e seus processos de preparação |
| US9125899B1 (en) | 2010-06-17 | 2015-09-08 | Stc.Unm | Modulators of GTPases and their use |
| CN103221388B (zh) * | 2010-07-09 | 2016-09-28 | 维理生物技术公司 | 用于抑制转移性肿瘤生长的新型磺酰胺化合物 |
| BR112013008527A2 (pt) * | 2010-12-17 | 2016-07-12 | Nerviano Medical Sciences Srl | derivados de pirazolo-quinazolina substituídos como inibidores de cinase |
| EP2757886A1 (de) | 2011-09-23 | 2014-07-30 | Bayer Intellectual Property GmbH | Verwendung 4-substituierter 1-phenyl-pyrazol-3-carbonsäurederivate als wirkstoffe gegen abiotischen pflanzenstress |
| US9120837B2 (en) | 2012-01-06 | 2015-09-01 | Molecular Insight Pharmaceuticals | Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX |
| HUE035739T2 (en) | 2013-01-14 | 2018-05-28 | Molecular Insight Pharm Inc | Triazine-based radiopharmaceuticals and radiological imaging agents |
| US10391119B2 (en) * | 2015-12-22 | 2019-08-27 | Nof Corporation | Lacrimal oily layer stabilizer and eye drops comprising same |
| WO2018211474A1 (en) | 2017-05-19 | 2018-11-22 | Trudell Medical International | Positive expiratory pressure device |
| USD903097S1 (en) | 2018-05-18 | 2020-11-24 | Trudell Medical International | Mask |
| USD874064S1 (en) | 2018-05-18 | 2020-01-28 | Trudell Medical International | Mask |
| USD893806S1 (en) | 2018-11-09 | 2020-08-18 | Trudell Medical Internationl | Mask and shroud |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN115607567A (zh) * | 2022-09-28 | 2023-01-17 | 长春工业大学 | 一种环保型改善心肌缺血的血液透析液 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1582619A (en) * | 1977-05-14 | 1981-01-14 | Centrala Ind Medicamente | Medicinal compositions for the treatment of gastritis gastro-duodenitis and duodenal ulcers |
| US5095026A (en) * | 1983-02-04 | 1992-03-10 | University Of Iowa Research Foundation | Prodrugs of carbonic anhydrase inhibitors |
| US5157044A (en) * | 1983-02-04 | 1992-10-20 | University Of Iowa Research Foundation | Analogs of carbonic anhydrase inhibitors and their use as topical IOP inhibitors |
| US4911920A (en) * | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| DE69120430D1 (de) * | 1990-12-18 | 1996-07-25 | Wellcome Found | Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen |
| AU653279B2 (en) * | 1991-12-30 | 1994-09-22 | Sanofi | Novel 2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| US6090834A (en) * | 1993-05-21 | 2000-07-18 | G.D. Searle & Co. | Substituted oxazoles for the treatment of inflammation |
| US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| CA2277954A1 (en) * | 1993-11-30 | 1995-06-08 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
| US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
| US5547975A (en) * | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
| JP3181190B2 (ja) * | 1994-12-20 | 2001-07-03 | 日本たばこ産業株式会社 | オキサゾール誘導体 |
| US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| JP3267300B2 (ja) * | 1995-02-13 | 2002-03-18 | ジー.ディー.サール アンド カンパニー | 炎症の治療のための置換イソオキサゾール |
| US5944021A (en) * | 1995-06-07 | 1999-08-31 | Rodriguez; Victorio C. | Therapeutic use of a carbonic anhydrase enzyme inhibitor for the treatment of brain edema |
| DE19600721A1 (de) * | 1996-01-12 | 1997-07-17 | Hoechst Ag | Verwendung von Inhibitoren des Carboanhydratase (CAH) zum Herstellen eines Medikaments zur Behandlung von Krebs |
| TR199801665T2 (xx) * | 1996-02-26 | 1998-12-21 | Advanced Research & Technology Institute | Makular �demin engellenmesi i�in karbonik anhidraz inhibit�rlerinin kullan�m�. |
| US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
| CA2372912C (en) * | 1997-10-14 | 2008-12-02 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| US5972986A (en) * | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| US6025353A (en) * | 1997-11-19 | 2000-02-15 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents |
| US5972684A (en) * | 1997-11-25 | 1999-10-26 | Incyte Pharmaceuticals, Inc. | Carbonic anhydrase VIII |
| ES2140354B1 (es) * | 1998-08-03 | 2000-11-01 | S A L V A T Lab Sa | Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2. |
| WO2000018741A2 (en) * | 1998-09-30 | 2000-04-06 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole compounds as cox-2 inhibitors |
| SE9803761D0 (sv) * | 1998-11-04 | 1998-11-04 | Synphora Ab | Method to avoid increased iridial pigmentation during prostaglandin treatment |
| ES2273688T3 (es) * | 1999-04-14 | 2007-05-16 | Dana-Farber Cancer Institute, Inc. | Procedimiento y composicion para el tratamiento de cancer. |
| US6465448B1 (en) * | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
| WO2001028548A1 (en) * | 1999-10-19 | 2001-04-26 | Texas Heart Institute | Treatment of heart disease with cox-2 inhibitors |
| PT1274700E (pt) * | 2000-01-03 | 2005-02-28 | Pharmacia Corp | Di-hidrobenzopiranos di-hidrobenzotiopiranos e tetra-hidroquinolinas para o tratamento de afeccoes mediadas por cox-2 |
| JP2003531824A (ja) * | 2000-02-01 | 2003-10-28 | ケイマン ケミカル カムパニー,インク. | フルプロステノールおよび関連プロスタグランジンF2α類似体の内部1,15−ラクトン、ならびに緑内障および眼高血圧の治療におけるそれらの使用 |
| US6448030B1 (en) * | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
| JP2002179657A (ja) * | 2000-05-26 | 2002-06-26 | Japan Tobacco Inc | 5−(4−アミノスルホニル−3−フルオロフェニル)−4−シクロヘキシル−2−メチルオキサゾールの結晶多形 |
| US20020009421A1 (en) * | 2000-06-01 | 2002-01-24 | Wilder Karol J. | Therapy following skin injury from exposure to ultraviolet radiation |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| EP1299123A2 (en) * | 2000-07-13 | 2003-04-09 | Pharmacia Corporation | Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
| US20020035148A1 (en) * | 2000-07-20 | 2002-03-21 | Ryuji Ueno | Treatment of ocular hypertension |
| WO2002013800A2 (en) * | 2000-08-11 | 2002-02-21 | Einar Stefansson | Method for the prevention and treatment of retinopathy |
| SE0004229D0 (sv) * | 2000-11-17 | 2000-11-17 | Aga Ab | Inhalation of nitric oxide |
| CA2456939A1 (en) * | 2001-08-10 | 2003-02-20 | Pharmacia Corporation | Carbonic anhydrase inhibitors |
-
2002
- 2002-08-07 US US10/213,793 patent/US20030100594A1/en not_active Abandoned
-
2003
- 2003-02-14 MX MXPA05001496A patent/MXPA05001496A/es not_active Application Discontinuation
- 2003-02-14 CA CA002495516A patent/CA2495516A1/en not_active Abandoned
- 2003-02-14 KR KR1020057002072A patent/KR20050056189A/ko not_active Ceased
- 2003-02-14 AU AU2003213062A patent/AU2003213062A1/en not_active Abandoned
- 2003-02-14 BR BR0313299-4A patent/BR0313299A/pt not_active IP Right Cessation
- 2003-02-14 BR BR0313282-0A patent/BR0313282A/pt not_active IP Right Cessation
- 2003-02-14 WO PCT/US2003/004469 patent/WO2004014430A1/en not_active Ceased
- 2003-02-14 AU AU2003225571A patent/AU2003225571A1/en not_active Abandoned
- 2003-02-14 JP JP2004527531A patent/JP2005539023A/ja not_active Withdrawn
- 2003-02-14 CN CNA038218801A patent/CN1681557A/zh active Pending
- 2003-02-14 CA CA002495502A patent/CA2495502A1/en not_active Abandoned
- 2003-02-14 WO PCT/US2003/004494 patent/WO2004014352A2/en not_active Ceased
- 2003-02-14 EP EP03709105A patent/EP1526895A2/en not_active Withdrawn
- 2003-02-14 MX MXPA05001497A patent/MXPA05001497A/es not_active Application Discontinuation
- 2003-02-14 JP JP2004527530A patent/JP2005539022A/ja not_active Withdrawn
- 2003-02-14 EP EP03784730A patent/EP1526869A1/en not_active Withdrawn
- 2003-02-14 PL PL03374994A patent/PL374994A1/xx unknown
-
2004
- 2004-04-19 US US10/827,075 patent/US20040198781A1/en not_active Abandoned
-
2005
- 2005-02-03 IL IL16668505A patent/IL166685A0/xx unknown
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102574782A (zh) * | 2009-10-21 | 2012-07-11 | 拜耳医药股份有限公司 | 取代的卤代苯氧基苯甲酰胺衍生物 |
| CN102574782B (zh) * | 2009-10-21 | 2014-10-08 | 拜耳知识产权有限责任公司 | 取代的卤代苯氧基苯甲酰胺衍生物 |
| CN102351793A (zh) * | 2011-08-30 | 2012-02-15 | 江苏正大清江制药有限公司 | 4-[3-(4-甲基苯基)-5-(三氟甲基)-1-氢-吡唑-1-基]苯磺酰胺的直接合成方法 |
| CN102351793B (zh) * | 2011-08-30 | 2013-11-06 | 江苏正大清江制药有限公司 | 4-[3-(4-甲基苯基)-5-(三氟甲基)-1-氢-吡唑-1-基]苯磺酰胺的直接合成方法 |
| CN109557309A (zh) * | 2018-12-04 | 2019-04-02 | 九江学院附属医院 | 碳酸酐酶-2作为检测标记物在肾结石诊断方面的应用 |
| CN109557309B (zh) * | 2018-12-04 | 2021-09-10 | 九江学院附属医院 | 碳酸酐酶-2作为检测标记物在肾结石诊断方面的应用 |
| CN111233786A (zh) * | 2020-02-04 | 2020-06-05 | 中国人民解放军军事科学院军事医学研究院 | 含五元杂环的苯磺酰胺类化合物及其制备方法和用途 |
| WO2021155781A1 (zh) * | 2020-02-04 | 2021-08-12 | 中国人民解放军军事科学院军事医学研究院 | 含五元杂环的苯磺酰胺类化合物及其制备方法和用途 |
| CN111233786B (zh) * | 2020-02-04 | 2021-11-26 | 中国人民解放军军事科学院军事医学研究院 | 含五元杂环的苯磺酰胺类化合物及其制备方法和用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| PL374994A1 (en) | 2005-11-14 |
| US20030100594A1 (en) | 2003-05-29 |
| AU2003225571A1 (en) | 2004-02-25 |
| IL166685A0 (en) | 2006-01-15 |
| WO2004014352A3 (en) | 2004-09-10 |
| CA2495516A1 (en) | 2004-02-19 |
| BR0313299A (pt) | 2005-06-14 |
| MXPA05001496A (es) | 2005-05-16 |
| JP2005539022A (ja) | 2005-12-22 |
| EP1526895A2 (en) | 2005-05-04 |
| AU2003213062A1 (en) | 2004-02-25 |
| KR20050056189A (ko) | 2005-06-14 |
| MXPA05001497A (es) | 2005-05-27 |
| CA2495502A1 (en) | 2004-02-19 |
| WO2004014352A2 (en) | 2004-02-19 |
| BR0313282A (pt) | 2005-10-18 |
| EP1526869A1 (en) | 2005-05-04 |
| WO2004014430A1 (en) | 2004-02-19 |
| US20040198781A1 (en) | 2004-10-07 |
| JP2005539023A (ja) | 2005-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2495502A1 (en) | Methods for treating carbonic anhydrase mediated disorders | |
| JP7252908B2 (ja) | S1p1活性を調節するための化合物およびその使用法 | |
| US20030220376A1 (en) | Methods for treating carbonic anhydrase mediated disorders | |
| ES2536191T3 (es) | Derivados de sulfonamida | |
| US20060025420A1 (en) | Pharmaceutical compositions for the treatment of female sexual disorders | |
| CN1976704A (zh) | 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途 | |
| CN101678107A (zh) | 用于治疗杜兴型肌营养不良的药物组合物 | |
| CN1671391A (zh) | 用于缓解疼痛的新方法及组合物 | |
| KR20160099084A (ko) | 치료 화합물의 결정질 형태 및 그의 용도 | |
| CN101068536A (zh) | S1p受体激动剂的剂量方案 | |
| JP2001506574A (ja) | シクロオキシゲナーゼ―2阻害剤およびロイコトリエンa4ヒドロラーゼ阻害剤を含有する免疫抑制効果をもつ配合物 | |
| CN1151794C (zh) | 治疗眼病的药用组合物 | |
| JP2010515769A (ja) | 疼痛を治療するためのモルホリンドーパミン作動薬 | |
| JP2023110030A (ja) | セペタプロストとRhoキナーゼ阻害剤との組み合わせ医薬 | |
| JP2004503601A (ja) | 眼のcox−2媒介疾患の処置及び予防におけるcox−2阻害剤の使用法 | |
| JP2000198734A (ja) | 胃運動性減弱および関連疾患の治療のための運動性増強薬 | |
| MX2007000694A (es) | Combinacion de un inhibidor selectivo de reabsorcion de noradrenalina y un inhibidor. | |
| CN1933832A (zh) | 离子通道调节剂 | |
| CN1638760A (zh) | 用环加氧酶-2选择性抑制剂和阿司匹林的组合治疗疼痛、炎症和炎症相关疾病 | |
| HK1080410A (en) | Methods for treating carbonic anhydrase mediated disorders | |
| CN115768433A (zh) | 含有司培前列素的医药制剂 | |
| JP2016029033A (ja) | 組合せ物 | |
| JP2008512436A (ja) | 片頭痛治療用の5−HT(1)受容体アゴニストとα2δリガンドの組み合わせ | |
| CN1386504A (zh) | 用于抑郁症和焦虑的联合治疗 | |
| HK40029829B (en) | Combination of sepetaprost and ripasudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1080410 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1080410 Country of ref document: HK |